CLL
Trial No. Principal Investigator Trial Name
TG Therapeutics UTX-TGR-304 Babu A phase 3, randomized study to assess the efficacy and safety of Ublituximab in combination with TGR-1202 compared to Obinutuzumab in combination with Chlorambucil in patients with Chronic Lymphocytic Leukemia (CLL)
TG Therapeutics UTX-TGR-204 Babu A multi-center, open-label, study to evaluate the safety and efficacy of Ublituximab (TG-1101) in combination with TGR-1202 for patients previously enrolled in Protocol UTX-TGR-304
CLL - 2nd Line
Trial No. Principal Investigator Trial Name
TG Therapeutics UTX-IB-301 Babu A phase 3, Randomized study to asses the efficacy and safety of Ublituximab in combination with Ibrutinib alone, in patients with previously treated high-risk Chronic Lymphocytic Leukemia